StockData
Ardelyx, Inc. logo

Ardelyx, Inc. (ARDX) company profile

ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3058% below fair value
$3.18+0.11 (+3.58%)

Close on Nov 17, 2026Market cap $792.42MP/E –Yield –

About Ardelyx

Pharmaceutical Preparations, SIC 2834

Ardelyx is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes small molecule therapies for unmet medical needs. It markets two products based on the active ingredient tenapanor: IBSRELA, which treats adults with irritable bowel syndrome with constipation, and XPHOZAH, which reduces serum phosphorus in adults with chronic kidney disease on dialysis. The company also develops pipeline candidates, including next-generation NHE3 inhibitors. Its end customers are adult gastrointestinal and kidney disease patients, reached through healthcare prescribers and commercial partners.

The company operates commercially in the United States through specialized sales forces and engages third-party contract manufacturers for drug production. Internationally, it establishes commercial and licensing partnerships across Canada, Japan, and China. The text does not disclose the location of the company's headquarters.

Summary of the business section of Ardelyx's latest annual report, written by StockData.

Company profile

Company

Legal name
Ardelyx, Inc.
Founded
2007
Headquarters
Fremont, CA
Address
34175 Ardenwood Blvd. 94555
Phone
(510) 745-7047
Employees
489, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
ARDX
Exchange
Nasdaq
IPO date
Jun 19, 2014
Shares outstanding
249M, Jul 30, 2026
Public float
$923.71M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1437402
CUSIP
039697107
ISIN
US0396971071
FIGI
BBG001WH4DQ3
Share class FIGI
BBG001WH4F33
LEI
549300F542QR4SXHCY32
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael RaabPresident & CEO, Director1,639,970
Eric Duane FosterChief Commercial Officer409,410
John E. BishopSee Remarks317,095
Susan HohenleitnerChief Financial Officer227,520
Mike KelliherChief Business Officer351,662
Joseph James ReillySee Remarks146,964
James Parker BradyChief Human Resources Officer259,090
Laura A. WilliamsChief Patient Officer371,620
Felecia EttenbergChief Legal Officer237,000
Rajani DinavahiChief Medical Officer201,000
Elizabeth A. GrammerSee Remarks302,866
Edward R. ConnerChief Medical Officer302,260
Justin A. RenzChief Financial Officer409,052
Robert BlanksSee Remarks314,421
David P. RosenbaumChief Development Officer525,970
Merdad ParseyDirector83,746
Onaiza Cadoret-ManierDirector178,156
David M. MottDirector9,887,572
Richard J. RodgersDirector439,998
Muna BhanjiDirector163,808
William C. Bertrand JRDirector303,052
Robert B. BazemoreDirector68,006

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$7.80M$8.32M$3.09M$90$81
FY2024$9.61M$4.75M$2.94M$78$81
FY2023$4.11M$10.06M$1.63M$96$80
FY2022$1.95M$4.05M$1.05M$44$78
FY2021$4.23M$39.20K$1.70M$17$71

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Michael Raab
President, Chief Executive Officer and Director
$797.00K–$2.95M$3.41M$627.64K$3.86K$7.80M-19%
Susan Hohenleitner
Chief Financial Officer
$120.93K$330.00K$735.95K$2.19M$56.42K–$3.44M–
John Bishop, Ph.D.
Chief Technical and Quality Officer
$240.00K–$1.00M$1.15M$116.51K$3.00K$2.51M–
Edward Conner, M.D.
Former Chief Medical Officer
$213.02K–$1.57M$1.84M––$3.62M–
Elizabeth Grammer, Esq.
Former Chief Legal and Administrative Officer
$527.13K–$708.00K$818.31K$246.70K$3.48K$2.30M-23%
Justin Renz
Former Chief Financial and Operations Officer
$464.43K–$1.58M$1.18M$250.43K$75.54K$3.55M+19%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 19, 2014
Offer price
$14.00
Securities offered
4,286,000
Gross proceeds
$60.00M
Exchange
Nasdaq
First trading day
Jun 19, 2014
First-day close
$14.11+0.8%
Lock-up ends (est.)
Dec 16, 2014

“Per Share Total Initial public offering price $ 14.00 $ 60,004,000 Underwriting discounts and commissions (1) $ 0.98 $ 4,200,280 Proceeds, before expenses, to us $ 13.02 $ 55,803,720 (1) See “Underwriting” for additional disclosure regarding underwriting discounts, commissions and estimated offering expenses.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“At December 31, 2025, we had 489 full-time employees, 93 of whom were engaged directly in research, development and manufacturing, 305 in sales and marketing and 91 in general and administrative activities.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 27, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 19, 2014IPOInitial public offering priced (424B4 prospectus)
Jun 9, 2014ListingRegistration of securities on an exchange (Form 8-A)
Jun 9, 2008Name changeName changed from NTERYX INC to Ardelyx, Inc.

See a number that looks wrong?